Quantification Differences and 18F-Fluciclovine Bladder Activity Comparison Between 2 Different Protocol Groups
| Parameter | Voiding protocol (n = 36) | Nonvoiding protocol (n = 123) | P |
| Age (y) | 67 (67, 63) | 69 (64, 74) | 0.21 |
| 18F-fluciclovine dose (MBq) | 381.1 (362.6, 399.6) | 381.1 (362.6, 392.2) | 0.49 |
| Aorta SUVmean | 1.5 (1.3,1.6) | 1.6 (1.4, 1.8) | 0.003 |
| Marrow SUVmean | 3.2 (2.7,3.8) | 3.4 (2.7, 4.0) | 0.12 |
| Liver SUVmean | 8.4 (7.5, 9.5) | 8.7 (7.5, 10.3) | 0.31 |
| Bladder SUVmax | 4.9 (3.4, 8.1) | 2.1 (1.1, 5.6) | 0.001 |
| Bladder SUVmean | 2.8 (2.1, 6.0) | 1.3 (0.5, 2.8) | <0.001 |
| Bladder SUVmean/aorta SUVmean ratio | 2.2 (1.5, 4.4) | 0.8 (0.4, 1.8) | <0.001 |
| Bladder SUVmean/marrow SUVmean ratio | 1.1 (0.6, 2.2) | 0.4 (0.2, 0.9) | <0.001 |
| Bladder SUVmean/liver SUVmean ratio | 0.4 (0.2, 0.7) | 0.2 (0.1, 0.3) | <0.001 |
| Volume (mL) | 18.0 (12.6, 30.6) | 51.9 (25.4, 87.1) | <0.001 |
| Bladder radioactivity (%) | |||
| Bladder visualized on maximum-intensity projection | 77.8% (28/36) | 46.3% (57/123) | <0.001 |
| Quantitation | |||
| Insignificant (bladder SUVmean < aorta SUVmean) | 19.4% (7/36) | 56.9% (70/123) | <0.001 |
| Mild (bladder SUVmean ≥ aorta SUVmean < marrow SUVmean) | 19.4% (7/36) | 21.1% (26/123) | 0.826 |
| Moderate (bladder SUVmean ≥ marrow SUVmean < liver SUVmean) | 38.9% (14/36) | 17.1% (21/123) | 0.005 |
| Intense (bladder SUVmean ≥ liver SUVmean) | 22.2% (8/36) | 4.9% (6/123) | <0.001 |
| Bladder volume (mL) | |||
| Insignificant | 36.5 (16.5, 66.0) | 71.2 (49.2, 104.8) | 0.039 |
| Mild | 15.4 (8.0, 18.1) | 31.1 (21.0, 73.9) | 0.015 |
| Moderate | 19.0 (12.60, 30.11) | 20.9 (15.5, 30.9) | 0.381 |
| Intense | 18.2 (12.6, 22.4) | 24.4 (17.7, 27.2) | 0.196 |
Data are median or percentage, with IQR or n in parentheses.